3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC). (September 2015) - Hellmann, M.D.; Rizvi, N.; Gettinger, S.N.; Goldman, J.; Chow, L.Q.; Juergens, R.; Borghaei, H.; Brahmer, J.; Shen, Y.; Harbison, C.T.; Nathan, F.; Ready, N.E.; et al.